BerGenBio ASA - Approval and publication of prospectus regarding listing of shares under the Share Option Programme
BerGenBio ASA - Approval and publication of prospectus regarding listing of
shares under the Share Option Programme
Bergen, Norway, 29 august 2018 - BerGenBio ASA (OSE:BGBIO) announces that the
Financial Supervisory Authority of Norway has approved a prospectus dated 29
August 2018 (the “Prospectus”) which has been prepared in connection with
listing of up to 2,860,012 new shares (“The New Shares”). The New Shares will be
issued by BerGenBio ASA (the “Company”) if and when holders of option rights
(the “Option Holders”) exercise their respective option rights under the
existing Share Option Programme for employees and certain members of the board
of directors in the Company and its subsidiary (the “Group”).
The Prospectus is personal to each Option Holder and does not constitute or form
a part of any public offer or solicitation to purchase or subscribe for
securities in the Company. The New Shares may only be subscribed for by Option
Holders pursuant to the terms of the Share Option Programme of the Group.
The Prospectus will, subject to regulatory restrictions in certain
jurisdictions, be available on the following website:
www.bergenbio.com/investors/reports/. Printed copies of the prospectus may also
be obtained free of charge at the offices of BerGenBio ASA, Jonas Lies vei 91,
5009 Bergen, Norway.
Advokatfirmaet Thommessen AS is acting as legal counsel to the Company.
-End-
About BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on
developing a pipeline of first-in-class AXL kinase inhibitors as a potential
cornerstone of combination cancer therapy. The Company is a world leader in
understanding the essential role of AXL kinase in mediating aggressive disease,
including immune evasive, drug resistant and metastatic cancer.
Contacts:
Richard Godfrey
CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie,
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
IMPORTANT NOTICE:
This announcement is not and does not form a part of any offer for sale of
securities.
Copies of this announcement are not being made and may not be distributed or
sent into the United States, Australia, Canada, Japan or any other jurisdiction
in which such distribution would be unlawful or would require registration or
other measures.
The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the “Securities
Act”), and accordingly may not be offered or sold in the United States absent
registration or an exemption from the registration requirements of the
Securities Act and in accordance with applicable U.S. state securities laws. The
Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
offering of the securities referred to in this announcement will be made by
means of a prospectus.
This announcement is not a prospectus for the purposes of Directive 2003/71/EC
(together with any applicable implementing measures in any Member State, the
“Prospectus Directive”). In any EEA Member State other than Norway that has
implemented the Prospectus Directive, this communication is only addressed to
and is only directed at qualified investors in that Member State within the
meaning of the Prospectus Directive, i.e., only to investors who can receive the
offer without an approved prospectus in such EEA Member State.
This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as “relevant persons”). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only to
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do
so.
The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice.
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Ekstern link: http://www.newsweb.no/index.jsp?messageId=458294
Nyheten er levert av OBI.
